Homocysteine, vitamin B6, and lipid in cardiovascular disease

被引:16
作者
Chan, SJ
Chang, CN [1 ]
Hsu, JC
Lee, YS
Shen, CH
机构
[1] Natl Cheng Kung Univ, Dept Biol, Tainan 701, Taiwan
[2] Chang Gung Univ & Mem Hosp, Dept Neurosurg, Taipei, Taiwan
[3] Chang Gung Univ & Mem Hosp, Dept Anesthesiol, Taipei, Taiwan
[4] Chang Gung Univ & Mem Hosp, Dept Cardiol, Taipei, Taiwan
关键词
homocysteine; vitamin B-6; lipid profile; cardiovascular disease;
D O I
10.1016/S0899-9007(02)00778-5
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
OBJECTIVES: Elevated homocysteine (Hey) is considered an independent risk factor for cardiovascular disease (CVD). An elevated plasma Hey level may interact with conventional CVD risk factors to further increase vascular disease risk. Therefore, we investigated the plasma levels of Hey. vitamin B-6 status (pyridoxal phosphate and pyridoxal), and lipid profile in patients with CVD. METHODS: Possible associations between sex, age, body mass index (BMI), and waist-to-hip ratio (WHR) to levels of plasma Hey and plasma Hey to vitamin B-6 status and lipid profile were examined. RESULTS: Plasma Hey level, body mass index, and waist-to-hip ratio were significantly higher in patients with CVD than in controls. Male CVD patients had significantly higher plasma Hey levels than did female patients. Plasma levels of pyridoxal phosphate and total B-6 aldehyde were significantly higher in male than in female patients. Plasma Hey levels of patients did not correlate to their plasma vitamin B-6 Status or to their lipid profiles. Plasma Hey level correlated positively with age, body mass index, and waist-to-hip ratio (P < 0.0001). CONCLUSIONS: This suggested that patients with CVD have higher levels of plasma Hey that are influenced by sex, age, body mass index, and waist-to-hip ratio and not by their plasma vitamin B-6 status and lipid profiles.
引用
收藏
页码:595 / 598
页数:4
相关论文
共 31 条
[1]  
Ballantyne Christie M., 1998, American Journal of Medicine, V104, p33S, DOI 10.1016/S0002-9343(98)00186-7
[2]   A QUANTITATIVE ASSESSMENT OF PLASMA HOMOCYSTEINE AS A RISK FACTOR FOR VASCULAR-DISEASE - PROBABLE BENEFITS OF INCREASING FOLIC-ACID INTAKES [J].
BOUSHEY, CJ ;
BERESFORD, SAA ;
OMENN, GS ;
MOTULSKY, AG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (13) :1049-1057
[3]  
CHANG SJ, 1999, VITAMIN B6 STATUS TA, P195
[4]   DISORDERED METHIONINE HOMOCYSTEINE METABOLISM IN PREMATURE VASCULAR-DISEASE - ITS OCCURRENCE, COFACTOR THERAPY, AND ENZYMOLOGY [J].
DUDMAN, NPB ;
WILCKEN, DEL ;
WANG, J ;
LYNCH, JF ;
MACEY, D ;
LUNDBERG, P .
ARTERIOSCLEROSIS AND THROMBOSIS, 1993, 13 (09) :1253-1260
[5]  
Dudman NPB, 1996, CLIN CHEM, V42, P2028
[6]   Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence [J].
Eikelboom, JW ;
Lonn, E ;
Genest, J ;
Hankey, G ;
Yusuf, S .
ANNALS OF INTERNAL MEDICINE, 1999, 131 (05) :363-375
[7]   The metabolism of homocysteine: pathways and regulation [J].
Finkelstein, JD .
EUROPEAN JOURNAL OF PEDIATRICS, 1998, 157 (Suppl 2) :S40-S44
[8]  
Folsom AR, 1998, AM J EPIDEMIOL, V148, P1187, DOI 10.1093/oxfordjournals.aje.a009608
[9]   Increased plasma homocysteine after menopause [J].
Hak, AE ;
Polderman, KH ;
Westendorp, ICD ;
Jakobs, C ;
Hofman, A ;
Witteman, JCM ;
Stehouwer, CDA .
ATHEROSCLEROSIS, 2000, 149 (01) :163-168
[10]   Homocysteine and vascular disease [J].
Hankey, GJ ;
Eikelboom, JW .
LANCET, 1999, 354 (9176) :407-413